Sales of the ingredient are expected to being in the country in the third quarter of 2013, according to a statement by the company. The approval came as a result of an 18-month process in conjunction with Pharma Marine’s Australian distributor, Pathway International.
“There is enormous potential for Calamarine to establish a significant position in the Australian market due to its unique value proposition with respect to sustainability and high DHA omega-3 fatty acid profile” said Wayne Coote, managing director of Pathway.
Pharma Marine sources its squid from fisheries in several locations around the world and touts its sustainability profile. The oil is derived from the offcuts of food grade calamari, and the fishery operations are certified by the Friends of the Sea organization.